Earnings summaries and quarterly performance for AbbVie.
Executive leadership at AbbVie.
Robert A. Michael
Detailed
Chief Executive Officer
CEO
AS
Azita Saleki-Gerhardt
Detailed
Executive Vice President, Chief Operations Officer
JR
Jeffrey R. Stewart
Detailed
Executive Vice President, Chief Commercial Officer
PC
Perry C. Siatis
Detailed
Executive Vice President, General Counsel and Secretary
ST
Scott T. Reents
Detailed
Executive Vice President, Chief Financial Officer
Board of directors at AbbVie.
BJ
Brett J. Hart
Detailed
Director
EJ
Edward J. Rapp
Detailed
Director
FH
Frederick H. Waddell
Detailed
Director
JL
Jennifer L. Davis
Detailed
Director
MB
Melody B. Meyer
Detailed
Director
RB
Rebecca B. Roberts
Detailed
Director
RJ
Robert J. Alpern
Detailed
Director
RS
Roxanne S. Austin
Detailed
Lead Independent Director
SE
Susan E. Quaggin
Detailed
Director
TC
Thomas C. Freyman
Detailed
Director
TJ
Thomas J. Falk
Detailed
Director
WH
William H.L. Burnside
Detailed
Director
Research analysts who have asked questions during AbbVie earnings calls.
CS
Christopher Schott
JPMorgan Chase & Co.
6 questions for ABBV
Also covers: AMGN, AMRX, BIIB +15 more
Mohit Bansal
Wells Fargo & Company
6 questions for ABBV
Also covers: AMGN, BMRN, BMY +16 more
Steve Scala
Cowen
6 questions for ABBV
Also covers: AZN, BMY, GSK +6 more
Terence Flynn
Morgan Stanley
6 questions for ABBV
Also covers: AMGN, ARVN, BIIB +17 more
Vamil Divan
Guggenheim Securities
6 questions for ABBV
Also covers: ABSI, ANIP, BHVN +7 more
DR
David Risinger
Leerink Partners
5 questions for ABBV
Also covers: AMGN, BMY, HALO +9 more
AH
Asad Haider
Goldman Sachs
3 questions for ABBV
Also covers: BMY, BNTX, JNJ +4 more
CL
Carter L. Gould
Barclays
3 questions for ABBV
Also covers: ALEC, AMGN, BMY +7 more
CB
Courtney Breen
AllianceBernstein
3 questions for ABBV
Also covers: AMGN, BMY, GILD +4 more
Geoffrey Meacham
Citi
3 questions for ABBV
Also covers: BIIB, BMY, GILD +6 more
LH
Luisa Hector
Berenberg
3 questions for ABBV
Also covers: AZN, BMY, MRK +1 more
TH
Trung Huynh
UBS Group AG
3 questions for ABBV
Also covers: ABOS, AMGN, BMY +5 more
CS
Chris Shibutani
Goldman Sachs Group, Inc.
2 questions for ABBV
Also covers: ALKS, BMY, BNTX +11 more
Geoff Meacham
Citigroup Inc.
2 questions for ABBV
Also covers: AMGN, BMY, GILD +8 more
JS
James Shin
Analyst
2 questions for ABBV
Also covers: AMGN, AUTL, BMY +7 more
Matthew Phipps
William Blair
2 questions for ABBV
Also covers: AGEN, AMGN, ARGX +8 more
SB
Simon Baker
Rothschild & Co Redburn
2 questions for ABBV
Also covers: AUTL
TA
Timothy Anderson
BofA Securities
2 questions for ABBV
Also covers: AMGN, AZN, BIIB +10 more
AH
Alexandria Hammond
Wolfe Research
1 question for ABBV
Also covers: AMGN, BMRN, BMY +6 more
CR
Christopher Raymond
Piper Sandler
1 question for ABBV
Also covers: AGIO, AMGN, ARDX +7 more
David Amsellem
Piper Sandler Companies
1 question for ABBV
Also covers: ALKS, AMGN, AMPH +27 more
DA
David Aslam
Piper Sandler
1 question for ABBV
ES
Evan Seigerman
BMO Capital Markets
1 question for ABBV
Also covers: AMGN, ARVN, BIIB +15 more
Gary Nachman
Raymond James
1 question for ABBV
Also covers: ACHV, ADMA, ALNY +9 more
JW
Jon Win
UBS
1 question for ABBV
TA
Tim Anderson
Bank of America
1 question for ABBV
Also covers: AMLX, BIIB, BMY +4 more
Recent press releases and 8-K filings for ABBV.
Cartesian Therapeutics outlines 2026 outlook
ABBV
- Enrollment is on track in the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis, with ~100 AChR Ab+ participants receiving six once-weekly outpatient infusions vs placebo and a primary endpoint of ≥3-point MG-ADL improvement at Month 4.
- The FDA accepted the IND for the seamless adaptive Phase 2 TRITON trial in myositis, set to begin in 1H 2026, with an interim analysis after 10 participants to inform a potential single pivotal trial.
- A Phase 1/2 (HELIOS) pediatric trial of Descartes-08 in juvenile dermatomyositis and other pediatric autoimmune diseases has been initiated.
- Two Nature Medicine publications detailed Descartes-08’s mechanism and reported that in Phase 2b MG patients, 57% of biologic-naïve participants achieved minimal symptom expression by Month 6 through Month 12 and the median prednisone dose was reduced by 55% at Month 12 with no CRS or ICANS observed.
- Current cash resources are expected to support ongoing operations, including completion of the Phase 3 AURORA and initiation of the Phase 2 myositis trials, into mid-2027.
1 day ago
Oncolytics Biotech proposes Nevada reincorporation, pivots U.S. strategy
ABBV
New Projects/Investments
- Proposed reincorporation from Alberta to Nevada, aligning with a shift to a U.S.-focused clinical strategy.
- Move reflects broader sector momentum, with biotech ETF FBT up 29% over the past year amid expectations of lower financing costs for clinical developers.
2 days ago
AbbVie denies acquisition talks with Revolution Medicines
ABBV
M&A
Guidance Update
- AbbVie publicly denied it was in advanced talks to acquire Revolution Medicines, stating it “is not in discussions”, contradicting a Wall Street Journal report.
- Speculation of a potential $15–20 billion+ valuation drove Revolution’s shares up ~30% intraday before the denial triggered a double-digit drop.
- An SEC filing flagged a possible $1.3 billion pre-tax hit tied to acquired in-process R&D and milestone expenses, and narrowed full-year 2025 adjusted EPS guidance to $9.90–$9.94 (from $10.61–$10.65) and Q4 EPS guidance to $2.61–$2.65 (from $3.32–$3.36).
- Investors now await AbbVie’s February 4 results for further detail on pipeline spending and the impact of potential acquisitions on near-term earnings.
3 days ago
AbbVie updates 2025 EPS guidance including IPR&D charges
ABBV
Guidance Update
- AbbVie’s Q4 2025 estimated acquired IPR&D and milestones expense is $1.3 billion pre-tax, reducing EPS by $0.71.
- Q4 2025 adjusted diluted EPS guidance including this expense is $2.61 – $2.65, versus prior guidance of $3.32 – $3.36 excluding the charge.
- Full-year 2025 adjusted diluted EPS guidance including Q4 IPR&D charges is $9.90 – $9.94.
- Q4 results are preliminary and subject to closing procedures; final results may differ.
3 days ago
Medincell reports H1 FY2025-26 consolidated results
ABBV
Earnings
New Projects/Investments
- Medincell’s total income rose 50% YoY to €14.1 m, with revenues of €11.6 m up 35% versus H1 FY2024.
- Operating expenses increased 22% to €20.8 m, resulting in an operating loss of €6.6 m, a 13% improvement year-over-year.
- Cash and equivalents plus low-risk financial investments stood at €53.5 m at September 30, 2025.
- UZEDY® royalties climbed 50% to €4.2 m, and Teva submitted an NDA for Olanzapine LAI to the FDA on December 9, 2025.
- Collaboration with AbbVie advanced preclinical and CMC activities, with a regulatory package for first human trials expected in 2026.
Dec 9, 2025, 5:02 PM
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
ABBV
- Preliminary data from the US extension of the phase III CELESTIMO study showed an 87.0% complete response rate and 27.8% CRS incidence (mostly Grade 1–2) in 54 patients with second-line+ follicular lymphoma
- In the phase Ib/II GO40516 study for relapsed/refractory large B-cell lymphoma, subcutaneous Lunsumio plus polatuzumab vedotin delivered a 77.5% ORR vs 50.0% and median PFS of 25.4 vs 6.4 months compared to rituximab/Polivy
- Five-year follow-up of IV Lunsumio in third-line+ FL reported a 78.5% overall survival rate and 54-month duration of CR rate of 52.0%; three-year SC data showed 74.5% ORR, 62.8% CR and a 30-month DOCR of 53.0%
- Lunsumio monotherapy is approved in over 60 countries, with the SC formulation recently approved by the European Commission and a US FDA decision expected soon
Dec 8, 2025, 9:30 PM
AbbVie reports Phase 1b/2 EPCORE-CLL-1 epcoritamab data in Richter transformation
ABBV
- Monotherapy arm (Arm 2A) in RT patients (n=42) showed an ORR of 57% (52% CR) first-line and 38% (29% CR) later-line; median OS was 27.5 months and 9.8 months, with median PFS of 8.5 and 2.9 months, respectively.
- Epcoritamab + lenalidomide (Arm 2B) in previously treated RT (n=11) achieved an ORR of 82% and CR rate of 73%; median PFS was 5.7 months, and 9-month OS was not reached.
- Epcoritamab + R-CHOP (Arm 2C) in frontline RT (n=30) delivered an ORR of 77% (63% CR), with median OS 16.4 months and PFS 16.0 months.
- Safety was consistent across arms: CRS occurred in up to 100% (mostly Grade 1/2) and resolved within days; treatment-related discontinuations and fatal events were infrequent.
Dec 8, 2025, 9:30 PM
AbbVie outlines strategy and growth at Piper Sandler Healthcare Conference
ABBV
M&A
Guidance Update
Product Launch
- AbbVie has executed roughly 30 transactions since early 2024, focusing on small bolt-on and platform deals (e.g., Nimble peptide platform, Capstan, 8Rx siRNA, Gubra obesity asset) while retaining capacity for larger M&A if compelling.
- The company reaffirms high single-digit revenue growth from 2024–2029 with EPS expected to grow faster via operating margin expansion—driven by SG&A leverage—while maintaining R&D spend at ~15% of sales.
- Skyrizi grew 46% YoY in Q3 2025 across IBD and psoriatic disease, benefiting from unique eight-week dosing and an on-body device; subcutaneous induction data in Crohn’s due H1 2026.
- The Parkinson’s franchise led by Vyalev 24-hour infusion pump targets >$400 million in 2025 revenue, with full-year guidance >$1 billion and multi-billion peak potential alongside tavapadon.
Dec 3, 2025, 1:30 PM
AbbVie outlines capital deployment and pipeline strategy at Piper Sandler Conference
ABBV
M&A
Guidance Update
- AbbVie has completed ~30 smaller-scale BD transactions since early 2024, focusing on platform and single-asset deals across immunology, oncology, neuroscience, eye care and obesity, and remains open to larger near-term revenue deals if compelling.
- The company maintains high single-digit revenue growth guidance for 2024–2029, with EPS expected to grow faster via operating margin expansion driven by SG&A leverage and continued R&D investment at ~15% of sales.
- Skyrizi grew 46% YoY in Q3 with balanced IBD and psoriatic disease uptake; an on-body sub-Q induction device for Crohn’s is expected to initiate submission after H1 2026 data.
- Pipeline highlights include phase II combination studies in IBD (TL1A, α4β7, IL-1), an obesity asset from the Gubra acquisition, and Rinvoq’s vitiligo label expansion targeting >$2 billion peak sales.
- In neuroscience, Vyalev’s 24-hour sub-Q infusion is guiding >$400 million in 2025 sales with a >$1 billion peak outlook alongside filed tavapadon; brexalosin neuroplastogen shows a rapid 2-hour psychedelic effect in MDD with a favorable 5-HT2B antagonism safety profile.
Dec 3, 2025, 1:30 PM
AbbVie outlines growth strategy and pipeline at Piper Sandler Healthcare Conference
ABBV
Guidance Update
New Projects/Investments
- AbbVie is deploying capital through ~30 small platform and single-asset transactions since early 2024 to bolster its pipeline and sustain growth into the next decade.
- The company reiterated high-single-digit revenue growth guidance for 2024–2029, with EPS expected to outpace sales via stable R&D spend (~15% of sales) and operating margin expansion through SG&A leverage.
- Commercially, Skyrizi grew 46% YoY in Q3, the IL-23 category in ulcerative colitis rose from ~4% to ~40% in 18 months, and a sub-Q induction on-body device submission is planned for H1 2026.
- Pipeline highlights include Rinvoq in vitiligo (>$2 billion peak sales), Vyalev Parkinson’s pump guiding >$400 million in 2025 and >$1 billion soon plus tavapadon filing, and Brotosilicin featuring a 2-hour neuroplastogen profile with 5-HT2B antagonism to reduce cardiac risk.
Dec 3, 2025, 1:30 PM
Fintool News
In-depth analysis and coverage of AbbVie.
Quarterly earnings call transcripts for AbbVie.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more